Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · NewAmsterdam Pharma Co N.V. (NAMS)

NewAmsterdam Pharma names Robert Gunning principal accounting officer effective August 10

Neutral Impact 2 of 5 leadership Written later

NewAmsterdam Pharma appointed Robert W. Gunning as its principal accounting officer on August 10, 2026, succeeding Louise Kooij, whose previously announced departure takes effect August 31, 2026. Gunning joined the company as Vice President, Controller on the same day, and his offer letter sets a $375,000 base salary and a 30% target bonus.

Key points

  • Robert W. Gunning, age 55, appointed principal accounting officer on August 10, 2026
  • Succeeds Louise Kooij, whose departure is effective August 31, 2026
  • Offer letter dated July 24, 2026: $375,000 base salary, 30% target bonus, 3,200 RSUs and options on 14,000 shares
  • Previously served as Vice President Finance and Corporate Controller at Y-mAbs Therapeutics from April 2022 to April 2026

The filing

CompanyNewAmsterdam Pharma Co N.V. (NAMS)
Form8-K, current report
Filed with the SECAug 14, 2026, 4:05 PM ET
Accession number0001193125-26-352186

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.